ClinicalTrials.gg
Active, not recruitingNCT04964934SERENA-6Updated Sep 23, 2026

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

A Phase 3 interventional study of AZD9833 and AZD9833 Placebo in ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 264 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Neoplasm Metastasis by AstraZeneca — 6 open to participants now, 23 under way, 14 of them phase 3. Neoplasm Metastasis · AstraZeneca.

Enrollment
17th of 55
315 · median 102
Started
2021
with 5 others
Phase 3
19 of 60
4 open now
Primary completion
2025-06
later than 8 of 22 live
Registered
47th of 60
by date

Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 17th largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2021, is one of 19 in phase 3, reaches primary completion later than 8 of the 22 other live ones, and was the 47th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 60 studies in Neoplasm Metastasis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neoplasm Metastasis by AstraZeneca, or all of them as a file.
02

Study summary

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Read the detailed description

Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.

This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.

The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.

Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:

  • palbociclib + anastrozole
  • palbociclib + letrozole
  • abemaciclib + anastrozole
  • abemaciclib + letrozole
  • ribociclib + anastrozole
  • ribociclib + letrozole

During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.

In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.

The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.

The researchers also want to know more about how safe AZD9833 is.

The trial participants will be split into 2 groups:

  • Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
  • Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo

A placebo looks like a treatment but does not have any medicine in it.

A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.

The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.

Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.

Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.

03

Conditions studied

  • ER-Positive HER2-Negative Breast Cancer

Keywords

  • Metastatic
  • Breast Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Breast Diseases
  • Physiological Effects of Drugs
  • Randomised
  • Multicentre
  • Double-Blind
  • Phase III
  • AZD9833
  • Next Generation Oral SERD
  • Anastrozole
  • Letrozole
  • Palbociclib
  • Abemaciclib
  • Ribociclib
  • Antagonists
  • Antineoplastic Agents
  • Estrogen Receptor Antagonists
  • Hormone Antagonists
  • camizestrant
  • ESR1m
  • Switch Treatment
  • Endocrine Therapy
  • Endocrine Resistance
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:

  • Have advanced breast cancer that is not able to be treated with surgery or radiation;
  • Have an ESR1 mutation in their cancer;
  • Have breast cancer that is HR-positive and -negative;
  • Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
  • Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
  • Are able to do their daily activities;
  • Are at least 18.

Full list of inclusion criteria:

  • Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or disease not amenable to resection or radiation therapy with curative intent;
  • Documentation of confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
  • Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
  • performance status of 0 or 1;
  • ESR1m detected by central testing of ctDNA with Guardant360® CDx;
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
  • Adequate organ and marrow function.

Exclusion criteria

EXCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:

  • Had certain types of tumors in the past that may come back;
  • Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
  • Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.

Full list of exclusion criteria:

  • Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
  • Known active uncontrolled or symptomatic , carcinomatous meningitis, or ;
  • Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
  • Patient with known or family history of severe heart disease;
  • Previous treatment with AZD9833, SERDs or fulvestrant;
  • Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
  • Persistent non-haematological toxicities ( Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
315 participants (actual)

Study arms

  • Experimental
    AZD9833 + palbociclib, abemaciclib or ribociclib

    The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)

    Drug: AZD9833 · Drug: Anastrozole placebo · Drug: Letrozole placebo · Drug: Palbociclib · Drug: Abemaciclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist · Drug: Ribociclib

  • Active comparator
    Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib

    The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)

    Drug: AZD9833 Placebo · Drug: Anastrozole · Drug: Letrozole · Drug: Palbociclib · Drug: Abemaciclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist · Drug: Ribociclib

Interventions

  • Dosage formulation: AZD9833 tablets will be administered orally

  • DrugAZD9833 Placebo

    Dosage formulation: AZD9833 placebo tablets will be administrated orally.

  • Dosage formulation: anastrozole tablets will be administered orally.

  • DrugAnastrozole placebo

    Dosage formulation: anastrozole placebo tablets will be administrated orally.

  • Dosage formulation: letrozole tablets will be administered orally.

  • DrugLetrozole placebo

    Dosage formulation: letrozole placebo tablets will be administered orally.

  • Dosage formulation: palbociclib tablets/capsules will be administered orally

  • Dosage formulation: abemaciclib tablets will be administered orally

  • Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

  • Dosage formulation: ribociclib tablets will be administered orally

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)

    PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death.

    Time frame: From randomization until the earlier of the progression event or death (approximately 2 years)

Secondary outcomes

  1. Progression-free survival 2 (PFS2)

    PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

    Time frame: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)

  2. Overall survival (OS)

    The OS is defined as the time from randomization to death due to any cause.

    Time frame: From randomization until the date of death due to any cause (approximately 5 years)

  3. Chemotherapy free survival

    Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.

    Time frame: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)

  4. Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1

    ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1.

    Time frame: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)

  5. Clinical benefit rate at 24 weeks (CBR24)

    CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment)

    Time frame: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)

  6. Change from baseline in EORTC QLQ-C30 scale scores

    Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: From baseline until second progression (approximately 5 years)

  7. Change from baseline in EORTC QLQ-BR23 scale scores

    Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: From baseline until second progression (approximately 5 years)

  8. Plasma concentration of AZD9833 at specified timepoints

    To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.

    Time frame: on Day 15 for each patient

07

Study locations

264 sites
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Hot Springs, Arkansas 71913, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Santa Rosa, California 92805, United States
  • Research Site
    Grand Junction, Colorado 81501, United States
  • Research Site
    Lone Tree, Colorado 80124, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Park Ridge, Illinois 60068, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Indianapolis, Indiana 46250, United States
  • Research Site
    Baltimore, Maryland 21202, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Fairhaven, Massachusetts 02719, United States
  • Research Site
    Foxborough, Massachusetts 02035, United States
  • Research Site
    Milford, Massachusetts 01757, United States
  • Research Site
    South Weymouth, Massachusetts 02190, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Oxford, Mississippi 38655, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Billings, Montana 59101, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    Ridgewood, New Jersey 07450, United States
  • Research Site
    Brooklyn, New York 11215, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    New York, New York 11355, United States
  • Research Site
    Shirley, New York 11967, United States
  • Research Site
    Goldsboro, North Carolina 27534, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Cincinnati, Ohio 45220, United States
  • Research Site
    Columbus, Ohio 43219, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    West Columbia, South Carolina 29169, United States
  • Research Site
    Knoxville, Tennessee 37916, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Bedford, Texas 76022, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Longview, Texas 75601, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
  • Research Site
    Midlothian, Virginia 23114, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Waukesha, Wisconsin 53226, United States
  • Research Site
    Birtinya, 4575, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1130, Austria
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Haskovo, 6300, Bulgaria
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Pleven, 5804, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Lévis, Quebec G6V 3Z1, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H2X 0C1, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Avignon, 84918, France
  • Research Site
    Brest, 29200, France
  • Research Site
    Clermont-Ferrand, 63050, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Limoges, 83000, France
  • Research Site
    Lorient, 56322, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Marseille, 13273, France
  • Research Site
    Metz-Tessy, 74370, France
  • Research Site
    Nîmes, 30029, France

Showing the first 100 of 264 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, Bianchini G, Iwata H, Fasching PA, Nowecki Z, Pascual J, Chen SC, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Jung KH, Kikawa Y, Baird RD, Habash R, Sugarman R, Fox S, Selvi Miralles M, Huang Bartlett C, Turner N. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. Oncologist. 2026 Aug 6;31(9):oyag278. doi: 10.1093/oncolo/oyag278. PubMed 42496653 ↗
  • Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13. PubMed 42442380 ↗
  • Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1. PubMed 40454637 ↗
  • Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18. PubMed 37070653 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jun 2025, 48 months.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 48 months is above that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Jul 16, 2021
StartActual
Jun 30, 2021
Primary completionActual
Jun 30, 2025
CompletionEst.
Sep 1, 2028
Results delay requested
Jun 24, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04964934
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
Jun 30, 2021
Primary completion
Jun 30, 2025
Completion
Sep 1, 2028 (estimated)
Last update
Sep 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion